^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Merkel Cell Carcinoma |
| Drug: | ITI-3000 (Immunostimulant) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
PharmaJet Partner Immunomic Therapeutics receives FDA Fast Track Designation for pDNA Vaccine for Skin Cancer
Published date:
12/13/2022
Excerpt:
PharmaJet®, a company that engineers precision delivery systems that overcome the challenges of vaccine and pharmaceutical companies, today announced that their partner Immunomic Therapeutics received FDA fast track designation (FTD) for the clinical study of their plasmid DNA vaccine ITI-3000 in patients with Merkel cell carcinoma (MCC), a rare but aggressive form of skin cancer.
